Skip to main content

NA-Semax Amidate vs Semaglutide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

NA-Semax Amidate

NA-Semax Amidate (N-Acetyl Semax Amidate) is a modified version of Semax with enhanced stability and potency. Also known as NASA, it provides stronger and longer-lasting nootropic effects than standard Semax.

Full details →

Semaglutide

Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030.

Full details →

Side-by-Side Comparison

AspectNA-Semax AmidateSemaglutide
MechanismMaintains Semax's core actions on BDNF, NGF, and monoamine systems with improved pharmacokinetics. The modifications enhance CNS penetration and extend duration of action.Semaglutide binds to and activates the GLP-1 receptor, a G-protein coupled receptor expressed in pancreatic beta cells, the hypothalamus, and the gastrointestinal tract. This triggers multiple downstream effects: (1) glucose-dependent insulin secretion from pancreatic beta cells, (2) suppression of glucagon release from alpha cells, (3) delayed gastric emptying, slowing nutrient absorption, (4) central appetite suppression via hypothalamic GLP-1 receptors, reducing hunger and increasing satiety. The peptide features a C-18 fatty diacid moiety attached via a linker to Lys26, enabling non-covalent albumin binding that protects against DPP-4 degradation and renal clearance.
Typical DosageIntranasal: 100-600mcg 1-2 times daily. Start with lower doses as it's more potent than standard Semax.For weight management (Wegovy): start at 0.25 mg weekly for 4 weeks, escalate to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly. Each escalation lasts 4 weeks. Maintenance dose is 2.4 mg weekly. For type 2 diabetes (Ozempic): start at 0.25 mg weekly for 4 weeks, increase to 0.5 mg. May increase to 1 mg, then 2 mg if additional glycemic control is needed. Oral semaglutide (Rybelsus): 3 mg daily for 30 days, then 7 mg daily. May increase to 14 mg daily. Oral Wegovy: 3 mg daily for 4 weeks, escalate to 7 mg, 14 mg, and 25 mg daily. Take on empty stomach with no more than 4 oz of water, 30 minutes before food.
AdministrationIntranasal spray is most common. Can be used sublingually. More stable than standard Semax in solution.Injectable: subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Store pens refrigerated (36-46°F) before first use; after first use, store at room temperature or refrigerated for up to 56 days. Oral: take on an empty stomach with a sip of plain water (no more than 4 oz). Wait at least 30 minutes before eating, drinking, or taking other oral medications. Do not split, crush, or chew tablets.
Side EffectsMay cause irritability, hair shedding (rare), or overstimulation at high doses. Generally well-tolerated.Very common (>10%): nausea (up to 44%), diarrhea, vomiting, constipation, abdominal pain. These are typically mild-to-moderate and decrease over time with dose escalation. Common (1-10%): headache, fatigue, dyspepsia, dizziness, bloating, flatulence, GERD, gastroenteritis. Notable: 'Ozempic face' (facial volume loss due to rapid weight loss), hair loss (telogen effluvium, reported in 25-33% of users in some studies), injection site reactions.
Best For

Key Differences

Unique to NA-Semax Amidate:

Unique to Semaglutide:

Detailed Analysis

Commonalities

NA-Semax Amidate and Semaglutide are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose NA-Semax Amidate for Cognitive Performance. Choose Semaglutide for Fat Loss, Gut Health.

Ready to Learn More?